A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411
This study is recruiting at 12 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 55 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- Irvine Center for Clinical Research · Irvine, CA
- Healthy Brain Clinic · Long Beach, CA
- Oakland Clinical · Oakland, CA
- Syrentis Clinical Research · Santa Ana, CA
Florida · 6
- K2 Medical Research, LLC · Maitland, FL
- Renstar Medical Research · Ocala, FL
- Charter Research - Winter Park/Orlando · Orlando, FL
- Conquest Research - Lake Nona · Orlando, FL
- Charter Research - Lady Lake/The Villages · The Villages, FL
- Conquest Research, LLC · Winter Park, FL
New York · 1
- Basil Clinical · Laurelton, NY
Virginia · 1
- Sana Research, LLC · Arlington, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.